Andrew Stephens, MD, PhD

Andrew Stephens, MD, PhD, has over 40 years of medical research experience, with 30 years in pharmaceutical research focusing on biomarkers and therapeutics for high unmet medical needs, including oncology, cardiovascular disease and cognitive decline. He has held leadership roles in start-ups, biotech, and large pharmaceutical companies, contributing to first-in-human and Phase I studies at Schering AG, Gilead, OSI, Bayer, Piramal, and Life Molecular Imaging. He played a key role in Phase III oncology and neuroimaging trials and led the global approval of 18F-florbetaben (Neuraceq). Currently, he oversees pre-clinical research, regulatory and medical affairs, clinical research, and operations as Chief Medical Officer at Life Molecular Imaging GmbH. His work includes pivotal Phase III PET radio tracer studies for imaging tau in Alzheimer’s and cardiac amyloidosis. Dr. Stephens has co-authored 300+ scientific papers with 7,300+ citations (h-index 45) and contributed to multiple patents.